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Despite the fact that harboring the apolipoprotein E4 (APOE4) allele represents the single greatest risk factor for late-onset
Alzheimer’s disease (AD), the exact mechanism by which apoE4 contributes to disease progression remains unknown. Recently,
we demonstrated that a 151 amino-terminal fragment of apoE4 (nApoE41-151) localizes within the nucleus of microglia in the
human AD brain, suggesting a potential role in gene expression. In the present study, we investigated this possibility utilizing
BV2 microglia cells treated exogenously with nApoE41-151. The results indicated that nApoE41-151 leads to morphological
activation of microglia cells through, at least in part, the downregulation of a novel ER-associated protein, CXorf56. Moreover,
treatment of BV2 cells with nApoE41-151 resulted in a 68-fold increase in the expression of the inﬂammatory cytokine, TNFα, a
key trigger of microglia activation. In this regard, we also observed a speciﬁc binding interaction of nApoE41-151 with the TNFα
promoter region. Collectively, these data identify a novel gene-regulatory pathway involving CXorf56 that may link apoE4 to
microglia activation and inﬂammation associated with AD.

1. Introduction
Alzheimer’s disease (AD) currently has a signiﬁcant global
impact. In the USA alone, over 5.7 million Americans suﬀer
from this progressive, irreversible brain disorder that
destroys memory and thinking skills [1]. A central tenet
underlying AD is chronic inﬂammation that may contribute
to the underlying pathology and neurodegeneration. Evi
dence documented for the past 30 years has proven the exis
tence of inﬂammation in AD, including activated microglia
within and surrounding senile plaques [2–5]. Despite this
wealth of evidence, the stimuli that led to microglia activation
and subsequent inﬂammation in AD are not well described.
One possible connection linking these two events may be
the apoE4 protein. The APOE4 allele represents the single
greatest risk factor for late-onset AD, and inheritance of
one copy of the APOE4 allele increases Alzheimer’s disease

(AD) risk fourfold, while two copies raises the risk tenfold
[6]. A recent study linking apoE4 to neuroinﬂammation in
AD demonstrated that apoE4-expressing microglia exhibit
higher innate immune reactivity after lipopolysaccharide
treatment and this in turn may promote neuroinﬂammation
in AD [7].
We recently documented the presence of an aminoterminal fragment of apoE4 1-151 (nApoE41-151) within the
nucleus of microglia cells in the human AD brain [8]. In
vitro, exogenous treatment of BV2 microglial cells with
nApoE41-151 led to uptake and traﬃcking to the nucleus
[8]. In the present study, we sought to examine the functional
consequences of nuclear localization of nApoE41-151 with a
working hypothesis that this fragment acts as a transcription
factor leading to gene expression changes within microglia.
Our results indicated that nApoE41-151 does regulate the
expression of several genes including a novel, previously
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uncharacterized gene, CXorf56. These ﬁndings have potential
broad implications implicating apoE4 to dementia risk per
haps through microglia activation and enhanced inﬂamma
tion in the AD brain.

2. Materials and Methods
2.1. Materials. The anti-CXorf56 rabbit polyclonal antibody
was purchased from Thermo Fisher Scientiﬁc (Rockford,
IL). Besides human CXorf56, this antibody has the highest
antigen sequence identity to mouse (100%) and rat (100%)
CXorf56. The mouse monoclonal anti-calnexin antibody
was purchased from Abcam Inc. (Cambridge, MA). MitoTracker Deep Red FM was purchased from Thermo Fisher
Scientiﬁc (Rockford, IL). Construction and puriﬁcation of
the amino-terminal fragment 1-151 for apoE4 (nApoE41
151) were contracted out to GenScript (Piscataway, NJ). The
anti-beta-actin monoclonal antibody was purchased from
ABclonal (Woburn, MA).
2.2. Cell Culture of BV2 Cells. BV2, murine microglial
cells, were maintained at 37°C and 6% CO2 in a humidi
ﬁed incubator. Cells were maintained in RPMI 1640 media
(HyClone) supplemented with 10% standard fetal bovine
serum (HyClone), 10% Cellgro MEM Nonessential Amino
Acid (Corning), and 10% penicillin-streptomycin (HyClone).
Cells were cultured in 50 ml T25 ﬂasks. For experimentation,
cells were grown on BioCoat poly-D-lysine glass multiwell
culture slides (Corning). All supplies were purchased from
Thermo Fisher Scientiﬁc Inc. (Waltham, MA). Treatment of
BV2 cells was undertaken by incubation with nApoE41-151
25 μg/ml for either 5 hours to assess mRNA expression or 24
hours prior to immunocytochemical or Western blot studies.
2.3. Chromatin Immunoprecipitation (ChIP-seq). Chromatin
immunoprecipitation (ChIP-seq) was employed to deter
mine what DNA sequences the nApoE41-151 fragment may
be binding to directly following treatment of BV2 cells.
ChIP-seq was performed according to the manufacturer’s
instructions (Abcam’s high-sensitivity ChIP kit (product num
ber: ab185913). nApoE41-151 pulled-down DNA sequences
were then outsourced (DNA Integrated Technologies) to be
sequenced. Numerous controls were included including a
positive control antibody (RNA polymerase II), a negative
control nonimmune IgG, and GAPDH primers to demon
strate the eﬃcacy of the kit reagents and protocol.
2.4. CXorf56 and TNFα Quantitative PCR. Primers were
designed to speciﬁcally amplify a portion of either the
CXorf56 or TNFα genes. Serine/arginine-rich splicing factor
11 (SFRS11) and EH domain-binding protein 1 (EHBP), two
ultraconserved elements that have invariant copy number in
mice, were used as reference genes. All primers were synthe
sized by Integrated DNA Technologies (Coralville, IA). For
TNFα, the forward sequence was ACGGCATGGATCTC
AAAGAC and the reverse was AGATAGCAAATCGGCT
GACG [9]. Primer eﬃciencies (E%) were conﬁrmed to be
between 90 and 110%. Primers were conﬁrmed to be speciﬁc
based upon melting proﬁles (Table 1).
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Table 1
Gene
SFRS11
EHBP
CXorf56

Oligo sequences (5 ′ -3 ′ )
AAATACCACCCAACAGTTT
AAGCCCTATACAGATGGAT
GAGTCTCCAATATCATCAGTAAGC
ACACATGCCACGATCAATG
GTGTTGCCAGGAAATAGTTTTCTTC
CCCAGGATCGCTAAC

E%
101
96
109

The total volume for each reaction was 20 μl and included
10 μl Fast EvaGreen qPCR Master Mix (Biotium Inc., Ca,
USA), 1 μl of each appropriate primer (10 μM), 4 μl of water,
and 4 μl of template cDNA. Each PCR reaction also included
a reverse transcription negative control to conﬁrm the
absence of genomic DNA in triplicate and a nontemplate
negative control to conﬁrm the absence of primer dimeriza
tion in triplicate. Real-time qPCR was run on a LightCycler
96 (Roche, Basel, Switzerland). The cycling conditions were
1 cycle of denaturation at 95°C for 3 min, followed by 40
cycles of ampliﬁcation (95°C for 30 sec, 55°C for 30 sec,
and 68°C for 30 sec) and one cycle of product melting
(95°C for 10 sec, 65°C for 60 sec, and 97°C for 1 sec). All sam
ples were ampliﬁed in triplicate, and the Cq value for each
reaction was determined by the LightCycler 96 SW1.1. Rela
tive diﬀerences in expression between treatments were deter
mined by the LightCycler 96 SW1.1 and conﬁrmed with the
ΔΔCt method.
2.5. Double-Stranded Small Interfering RNA Synthesis and
Transfection. Double-stranded small interfering RNAs (siRNAs) were synthesized by Integrated DNA Technologies
(Coralville, IA). Two diﬀerent siRNAs were synthesized to
target CXorf56 mRNA and termed siRNA(2) and siRNA(3),
respectively. A third control siRNA was designed as a nega
tive control and consisted of a scrambled sequence. BV2
microglia cells were approximately 60% conﬂuent prior to
transfection. Transfection was achieved by combining 25 μl
of Opti-MEM Reduced Serum Media (Thermo Fisher Scien
tiﬁc), 0.75 μl of Lipofectamine RNAiMAX Transfection
Reagent (Thermo Fisher Scientiﬁc), and 1.25 pmol of the
appropriate siRNA and pipetting the mixture directly onto
the plated cells in 48-well plates. A TYE 563-labeled siRNA
was used as a positive transfection control, a HPRT-s1 siRNA
was used as an endogenous gene positive control, and a
scrambled siRNA was used as a negative control. Treatments
were for 5 hours to assess CXorf56 mRNA downregulation or
24 hours to assess protein levels.
2.6. Total RNA Extraction and cDNA Synthesis. Total RNA
was extracted from cells with the Direct-zol RNA MicroPrep
Kit (Zymo Research Corp., CA, USA) according to manufac
turer’s instructions. Genomic DNA was eliminated using
TURBO DNAse as described by the manufacturer (Life
Technologies, CA). RNA quality was assessed using spectro
photometry and gel electrophoresis. Total cDNA was gener
ated from 1 μg of total RNA using qScript cDNA SuperMix
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(QuantaBio, MA, USA). Prior to use in qPCR, cDNA was
diluted 1 : 2 with water.
2.7. Confocal Microscopy. Following treatment studies, BV2
cells were ﬁxed by incubating cells in 4% paraformaldehyde
for 23 minutes. For antibody labeling, cells were washed with
0.1 M Tris-buﬀered saline (TBS), pH 7.4, and pretreated with
3% hydrogen peroxide in 10% methanol to block endogenous
peroxidase activity. Slides were subsequently washed in TBS
with 0.1% Triton X-100 (TBS-A) and then blocked for thirty
minutes in TBS-A with 3% bovine serum albumin (TBS-B).
Slides were further incubated overnight at room tempera
ture with the anti-His rabbit antibody (1 : 2,000). Following
two washes with TBS-A and a wash in TBS-B, slides were
incubated with the anti-rabbit HRP-conjugated secondary
antibody. Visualization was accomplished by using a tyra
mide signal ampliﬁcation kit (Molecular Probes, Eugene,
OR) consisting of Alexa Fluor 488-labeled tyramide (green,
Ex/Em = 495/519). Slides were mounted using ProLong Gold
Antifade Mountant with DAPI (Molecular Probes).
2.8. Microsome Isolation and Western Blot Analysis. ERenriched fractions from BV2 microglia cells were prepared
using a microsome isolation kit (BioVision, Milpitas, CA)
according to the manufacturer’s instructions. Western blot
analysis was performed as previously described [10]. Pro
teins were separated by 15% SDS-PAGE and transferred to
nitrocellulose. Transferred slabs were stained in Coomassie
blue to verify equal loading between samples. Membranes
were incubated in a CXorf56 antibody (1 : 500) or a calnexin
antibody (1 : 100) overnight at 4°C, and primary antibodies
were visualized using the goat anti-rabbit HRP-linked sec
ondary antibody, incubated for 1 hour at room temperature
(1 : 5,000) (Jackson’s Laboratory, West Grove, PA), followed
by ECL detection. To conﬁrm equal protein loading, Western
blot analysis was also carried out using a beta-actin antibody
at 1 : 50,000). Densitometry analysis was performed using the
Image Studio software, version 5.2.5 (LI-COR Biosciences).
2.9. Quantiﬁcation of Morphological Changes and Statistical
Analysis. NeuronJ is distributed as a plugin for ImageJ, free
image analysis software distributed by the National Institutes
of Health. Semiautomated tracing with NeuronJ has been
shown to be as accurate as both fully manual [11] and fully
automated tracing [12]. BV2 microglia cells were treated as
described above with siRNAs for 24 hours. Following treat
ments, two-dimensional 20x images were obtained using
bright-ﬁeld microscopy. Images from each well were taken
in a random location and converted to the proper format
for use with the NeuronJ software. Following conversion,
the number of cells and number of pseudopods in each image
were manually counted. To assess the length of the pseudopods, the neuron tracing feature of NeuronJ was employed.
After pseudopods were traced, a text ﬁle containing measure
ments of the lengths of all the pseudopods was exported to
Excel for analysis. Statistical diﬀerences in this study were
determined using Student’s two-tailed t-test employing
Microsoft Oﬃce Excel.
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2.10. DNA Mobility Shift Assays. The binding reactions were
created by combining 2 μl of 10x binding buﬀer (Thermo Sci
entiﬁc Cat. #20148), 1 μl of 50% glycerol, 1 μl of 100 mM
MgCl2, 1 μl of 1 μg/μl poly(dI · dC), 1 μl of 1% NP-40, and
20 fmol of TNFα promoter region DNA. The murine TNFα
promoter region DNA was synthesized and biotinylated at
the 5 ′ end by Integrated DNA Technologies Inc. utilizing
the following sequence: ATGCTTGTGTGTCCCCAACTT
TCCAAATCCCCGCCCCCGCGATGGAGAAGAAACCG
AGACAGAAGGTGCAGGGCCCACTACCGCTTCCTCC
AGATGAGCTCATGGGTTTCTCCACCAAGGAAGTTT
TCCGCTGGTTGAATGATTCTTTCCCCGCCCTCCTCT
CGCCCCAGGGACATATAAAG GCAGTTGTTGGCAC
ACCA. Finally, either 3.6 μg of nApoE41-151 protein frag
ment or 3.6 μg of full-length ApoE4 protein was added with
the addition of nuclease-free water to each reaction to bring
the ﬁnal volume to 20 μl. All reactions were incubated at
room temperature for twenty minutes.
Following preincubation of DNA with protein, a 5% TBE
precast polyacrylamide gel (Bio-Rad Cat. #4565013) was pre
pared with 0.5x TBE as the loading buﬀer. The gel was pre
electrophoresed at 100 V for 30 minutes. 5 μl of 5x loading
buﬀer (Thermo Scientiﬁc Cat. #20148) was mixed into each
reaction; 20 μl of each mixture was loaded, and reactions
were separated at 100 V. Following separation, reactions
were transferred at 100 V for 30 minutes onto a Biodyne™
B Precut Modiﬁed Nylon Membrane, 0.45 μm (Thermo Sci
entiﬁc Cat. #77016). Following the transfer, the DNA on the
membrane was cross-linked at a distance of approximately
0.5 cm from the membrane for 5 minutes with a 254 nm
handheld UV lamp. The Biotin-labeled DNA was detected
using the Chemiluminescent Nucleic Acid Detection Mod
ule (Thermo Scientiﬁc Cat. #89880) according to the manu
facturer’s instructions.
2.11. Cytokine ELISA Assays. To quantify the levels of
secreted TNF-alpha or IL-1beta in BV2 cells, mouse TNFalpha or IL-1beta Quantikine ELISA kits from R&D Systems
was employed according to the manufacturer’s instructions.
Brieﬂy, 50 μl of standard, control, or sample was added in
duplicate to ELISA plates, incubated at room temperature
for 2 hours followed by 5 washes in wash buﬀer. Next,
100 μl of conjugate was added to each well, sealed, and incu
bated at room temperature for 2 hours followed by a wash
step. 100 μl of substrate solution was added for 30 minutes
followed by 100 μl of stop solution. The ELISA plate was read
at 450 nm, and concentrations (pg/ml) were determined
using a standard curve consisting of either recombinant
mouse TNF-alpha or IL-1beta.

3. Results
3.1. CXorf56 Is an ER-Associated Protein. The purpose of the
current study was to elucidate the possible functional conse
quences of nuclear traﬃcking by nApoE41-151 with our major
hypothesis being the fragment acts as an enhancer or a
repressor of gene transcription. In the CNS, both microglia
and astrocytes synthesize and secrete apoE4 [13, 14]. In a
previous study, we documented the presence of a 17 kDa
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Figure 1: Nuclear localization of an amino-terminal fragment of apoE4 is conﬁrmed in microglia cells but not in astrocytes. (a–c) U87 cells,
representing an astrocytic cell line, were plated on glass chamber slides in normal growth media and treated for 24 hours with the nApoE41-151
fragment. Following treatment, cells were ﬁxed and immunocytochemistry was carried out using an anti-His rabbit, polyclonal antibody at
1 : 2,000, followed by the HRP-conjugated secondary antibody at 1 : 200 (see Materials and Methods for details). Under these experimental
conditions, although there was evidence of the cytoplasmic uptake of the fragment (a), little nuclear localization of the nApoE41-151
fragment was observed following treatment (c, merge). Scale bars represent 10 μm. (d) A representative set of images showing nuclear
localization in the microglial cell line, BV2, following exogenous treatment with the nApoE41–151 fragment. BV2 microglial cells were
placed on glass chamber slides in normal growth media and treated for 24 hours with the nApoE41–151 fragment. Following treatment,
cells were ﬁxed and immunocytochemistry was carried out as described above. Double-label immunoﬂuorescence confocal z-stacks were
acquired to detect nApoE41–151 (green) together with DAPI (blue). The merged images indicated the strong nuclear and cytoplasmic
presence of the amino-terminal fragment following extracellular incubation of BV2 cells.

amino-terminal fragment of apoE4 in the nucleus of microglia in human postmortem AD brain sections but found no
evidence for this fragment in the nucleus of astrocytes [8].
In addition, exogenous treatment of BV2 microglia cells with
the corresponding protein fragment (nApoE41-151) led to
uptake and traﬃcking to the nucleus [8, 15]. To conﬁrm
these ﬁndings, BV2 cells representing microglia and U87
cells representing astrocytes were treated with or without
nApoE41-151 and labeled with an anti-His antibody to track
the uptake and localization of the fragment following treatment. As shown in Figure 1, although both cell lines took
up the fragment from the surrounding media, nuclear localization was only evident within the BV2 microglia cells
(Figure 1(d)). Based on these results, all experiments were
performed on BV2 microglia cells due to the fact that nuclear
localization of nApoE41-151 would be necessary a priori in
order for the fragment to regulate gene transcription directly.
As an initial approach, experiments were undertaken
using DNA harvested from BV2 microglia cells and chromatin immunoprecipitation (ChIP-seq) analyses to determine
what DNA sequences the nApoE41-151 fragment may be
binding to directly. Using this approach, a DNA sequence

pulled down by immobilized nApoE41-151 was mapped to a
5 ′ region on chromosome 18 designated Gm8181 in the
murine genome (BV2 cells are of murine origin). This DNA
sequence was pulled down on three separate occasions
employing chromatin immunoprecipitation. Other sequences
that were also pulled down were too degraded to conﬁrm
sequence identity. Examination of this sequence revealed an
uncharacterized gene on human chromosome X termed
CXorf56. Although the two genes are named diﬀerently in
the mouse and human, the proteins are virtually identical with
there being one amino acid out of 222 that is diﬀerent between
the two species (99.5% sequence identity). Therefore, for clar
iﬁcation purposes, we will refer to the mouse gene as the
CXorf56 homologue and the mouse protein as CXorf56.
Although the CXorf56 gene has recently been linked to a
form of intellectual disability [16], the subcellular localization
and function of the expressed protein in the CNS are currently not known. Thus, we performed confocal immunoﬂu
orescence studies in microglia cells using an antibody speciﬁc
to the mouse CXorf56 protein to determine its possible cellu
lar localization. Perinuclear cytoplasmic labeling of this antibody was evident in BV2 microglia cells. Double-label
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Figure 2: Subcellular localization of the CXorf56 protein to the ER in microglial, BV2 cells. (a–c) Representative images from confocal
immunoﬂuorescence in BV2 cells utilizing an anti-CXorf56 antibody (a, green) and an anti-calnexin antibody, an ER-speciﬁc marker (b,
red), with the overlap image shown in (c) (yellow). DAPI nuclear labeling in blue is shown in (c). A strong perinuclear colocalization
between these two antibodies was evident (c). (d) Western blot analysis was carried out using BV2 whole cell lysates (left lanes) or
enriched ER fractions (right lanes), and transferred proteins were probed with either the CXorf56 antibody (left panel, 1 : 500) or with the
ER marker, calnexin (right panel, 1 : 1,000). The results indicated a 34 kDa immunoreactive band by the CXorf56 antibody in the ER
fraction to which calnexin was also immunolabeled (right panel, 90 kDa band). Data are representative of three independent experiments.

confocal microscopy studies ruled out a staining in mito
chondria as evidenced by the lack of colocalization of the
anti-CXorf56 antibody with known mitochondrial markers
(Fig. S1). In contrast, a strong colocalization of CXorf56 with
calnexin, a speciﬁc endoplasmic reticulum (ER), was evident
following confocal microscopy analysis (Figures 2(a)–2(c)).
To conﬁrm these immunocytochemistry ﬁndings, Western
blot analysis was performed in whole-cell BV2 extracts or
ER-enriched fractions. ER-enriched fractions were validated
following immunoblotting with calnexin (Figure 2(d), right
panel). Immunoblotting with the anti-CXorf56 antibody
revealed a speciﬁc band in the ER-enriched fraction corre
sponding to the correct predicted molecular weight of
CXorf56 at 34 kDa (Figure 2(d), left panel). Additional exper
iments utilizing mouse liver microsomes that are enriched
with ER conﬁrmed the high expression of CXorf56 within
the ER (Fig. S2). Taken together, these results identify
CXorf56 as an ER-speciﬁc protein.

3.2. The CXorf56 Protein Is Required to Maintain Microglia
Cells in a Quiescent Morphological Phenotype. To assess a
possible function for CXorf56, we employed doublestranded small interfering RNAs (siRNAs) to induce shortterm silencing of the CXorf56 gene expression. For these
experiments, we designed three diﬀerent siRNAs: a scram
bled siRNA sequence that would serve as a negative control
and two siRNAs (siRNA(2) and siRNA(3)) designed to spe
ciﬁcally target CXorf56 mRNA for degradation. BV2 microg
lia cells were treated for 5 hours with either one of these
constructs followed by real-time quantitative PCR (qPCR)
using SFSR11 and EHBP as internal controls for expression
(see Materials and Methods for details). Control experi
ments indicated that >90% of BV2 cells were successfully
transfected following treatment of cells with siRNA con
structs. In contrast to the negative siRNA control, treatment
with siRNA(2) or (3) led to a 40% and 50% downregulation,
respectively, of CXorf56 mRNA (Figure 3(a)). It is
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noteworthy that increasing concentrations of siRNA above
what is shown in Figure 3 did not lead to a greater knock
down of CXorf56 mRNA. At this time, it is not known
why we were not able to achieve a greater degree of
knockdown but it could be related to a number of factors
including proper cellular localization, incorrect 3D struc
ture, or inaccessibility due to bound proteins. Veriﬁcation
of CXorf56 protein knockdown was obtained following
Western blot analysis (Figure 3(b)). Confocal microscopy
using anti-CXorf56 demonstrated a decrease in the stain
ing intensity as compared to nontreated controls or BV2
cells treated with the negative siRNA control construct
(Figures 3(c)–3(f)). Interesting, in addition to a decrease
in CXorf56 staining intensity, we also observed a morpho
logical change following CXorf56 knockdown. As depicted
in Figures 3(e) and 3(f), microglia cells became elongated
and bipolar in appearance.
To further characterize a potential morphological role
for CXorf56, we carried out bright-ﬁeld, phase-contrast
microscopy with quantitative analysis using the ImageJ
software. Visually, knockdown by either siRNA(2) or (3)
resulted in cells extending out long pseudopods (arrowheads,
Figure 4(d)). Cells also appeared ﬂatter with bright, vesicular
structures within the cytoplasm (arrow, Figure 4(d)). A
quantitative analysis indicated a signiﬁcant increase in both
the percent of microglia with pseudopods (Figure 4(e)) as well
as the overall length of pseudopods per cell (Figure 4(f)).
Taken together, these data suggest that the knockdown of
the CXorf56 protein leads to a morphological shift to an acti
vated state that is characterized by extension of pseudopods
as well as in increase in vacuolar appearance [17–19].
3.3. An Amino-Terminal Fragment of apoE4 Leads to
Microglia Activation. Next, we sought to determine a role
for apoE4 in activating microglia using BV2 cells as a model
system. We recently demonstrated a key role for an aminoterminal fragment of apoE4 1-151 (nApoE41-151) localizing
to the nucleus of microglia in the human AD brain [8]. In
addition, treatment of BV2 microglia cells with nApoE41
151 leads to an uptake and traﬃcking of nApoE41-151 to the
nucleus [8, 15]. We hypothesized that this fragment may be
acting as a transcription factor changing the expression of
proteins that may promote the inﬂammation associated with
AD. To test this directly in the current study, we incubated
BV2 microglia cells with 25 μg/ml nApoE41-151 or an equiva
lent concentration of full-length apoE4 and assessed any
morphological and/or functional changes that may result in
connection with CXorf56. This concentration of nApoE41
151 is within the range of the normal concentration of apoE
that has been documented in the human brain (3-5 μg/ml)
[20]. A concentration of 25 μg/ml was chosen because we
obtained inconsistent results with lower concentrations of
nApoE41-151, and overall, 10 μg/ml nApoE41-151 did not lead
to a decrease in the level of the CXorf56 protein (see below).
Treatment of BV2 microglia cells with nApoE41-151 resulted
in a signiﬁcant downregulation of the CXorf56 homologue
mRNA (blue bar, Figure 5(a)) while full-length apoE4 had
no signiﬁcant eﬀect (red bar, Figure 5(a)). In addition, we
observed a 73.5% decrease in the expression of the CXorf56
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protein as demonstrated by Western blot analysis following
incubation of BV2 cells with a 25 μg/ml nApoE4 fragment,
while 10 μg/ml had no signiﬁcant eﬀect (Figures 5(a)–5(c)).
Confocal immunoﬂuorescence microscopy demonstrated a
decrease in the staining intensity of CXorf56 following treat
ment with nApoE41-151 (Figures 5(d) and 5(e)). Moreover,
there was a clear shift in the morphology of cells that was
similar to what was observed following CXorf56 knockdown
with siRNA (arrowheads, Figure 5(e)); cells became elon
gated and bipolar, sending out long pseudopods. The actions
of nApoE41-151 were independent of cell toxicity and subse
quent degradation of the CXorf56 protein as assessed by the
release of LDH in media by BV2 microglia cells (Fig. S3).
These data suggest that nApoE41-151 may promote a mor
phological shift of microglia cells via downregulation of the
CXorf56 protein.
3.4. An Amino-Terminal Fragment of apoE4 Speciﬁcally
Binds to the TNFα Promoter Region and Leads to Increased
Secretion of TNFα and IL-1beta. Activated microglia express
proinﬂammatory cytokines such as tumor necrosis factor
alpha (TNFα) as well as IL-1beta, which are well-known
signature cytokines of microglia activation. Treatment of
BV2 microglia cells with nApoE41-151 leads to a 24.5-fold
increase in TNFα expression (Figure 6(a)). Paralleling the
mRNA expression, we documented a signiﬁcant, 68-fold
increase in the level of secreted TNFα protein in the media
following treatment of BV2 microglia cells with nApoE41-151
(Figure 6(b)). As a control, we also tested whether this was
related directly to the apoE4 fragment by testing myoglobin
that consists of roughly the same number of amino acids
and molecular weight. Myoglobin consists of 153 amino
acids and has a molecular weight of 16.7 kDa. As shown in
Figure 6(b), exposure of BV2 cells to myoglobin at the same
concentration as to nApoE41-151 did not lead to an increase
in secreted TNFα (red bar, Figure 6(b)). Moreover, we
noticed qualitatively no change in the morphology with
myoglobin as compared to the nApoE41-151. Similar to the
results with TNFα, we also observed a 59-fold increase in
the secretion of IL-1beta following treatment of BV2 cells
with nApoE41-151 (Figure 6(c)), with little eﬀect observed
following treatment with myoglobin. These results suggest
a speciﬁc action of nApoE41-151 on BV2 cells versus a more
general microglial response.
To test whether the nApoE41-151 fragment interacts
speciﬁcally with the TNFα DNA promoter region, gel mobil
ity shift assays were performed. Biotinylated DNA corre
sponding to the upstream 200 bp promoter region of TNFα
in the mouse was incubated with nApoE41-151, and a signiﬁ
cant degree of DNA retardation was observed (Figure 6(d)).
This shift was somewhat attenuated by preincubating the
nApoE41-151 fragment with an anti-His tag antibody that
speciﬁcally recognizes the amino-terminal fragment of
nApoE41-151 (far right panel, Figure 6(d)). In a ﬁnal set of
experiments, we directly compared the ability of full-length
apoE4 to bind to the TNFα promoter region. As shown in
Figure 6(e), in contrast to the nApoE41-151 fragment, fulllength apoE4 did not lead to a mobility shift, suggesting
that the binding of nApoE41-151 is a speciﬁc event. Taken
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Figure 3: Conﬁrmation of CXorf56 knockdown in BV2 microglial cells following treatment with siRNAs. (a) BV2 cells were treated for 5
hours with a scrambled siRNA sequence (Neg. siRNA Ctl, green bar) or two designed sequences (siRNA2, blue bar or siRNA3, red bar)
targeted to the CXorf56 open reading frame. Following treatment, total RNA was extracted and RT qPCR was performed. In contrast to
the negative siRNA control, siRNA(2) and siRNA(3) led to a 40% and 58% downregulation, respectively, of CXorf56 mRNA. ∗ denotes
signiﬁcant diﬀerence between scrambled negative control and siRNA(2), p = 0 0003. # denotes signiﬁcant diﬀerence between negative
control and siRNA(3), p = 0 0005. (b) Western blot analysis utilizing an anti-CXorf56 antibody (1 : 500) conﬁrmed the decreased
expression of the CXorf56 protein following treatment of BV2 cells for 24 hrs with siRNA2 (middle lane) or siRNA3 (far right lane). Beta
actin was employed as a loading control utilizing an anti-beta-actin antibody (1 : 50K), bottom panel. Data are representative of three
independent experiments ± S D (c–f) Representative confocal immunoﬂuorescence images utilizing an anti-CXorf56 antibody in BV2
cells following treatment with siRNAs for 24 hours with nontreated cells (c), negative siRNA control (d), siRNA(2) (e), and siRNA(3) (f).
A decrease in staining intensity with the anti-CXorf56 antibody was observed following treatment with siRNA2 (e) and to a lesser extent
with siRNA3 (f). Note also the apparent change in morphology following treatment with extended, bipolar pseudopods in (e) and (f).
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Figure 4: Downregulation of the CXorf56 protein leads to morphological changes in BV2 microglia cells. (a–d) BV2 cells were untreated (a)
or treated for 5 hours with scrambled negative control siRNA (b), siRNA2 (c), or siRNA3 targeting the open reading frame CXorf56 (d).
Following treatment, bright-ﬁeld, phase-contrast images were captured. In contrast to untreated or cells treated with the siRNA negative
control, cells treated with targeted siRNAs led to changes in morphology from round, compact cells to cells that were ﬂattened and
extended long pseudopods (arrowheads, c and d) and or were highly vacuolized (arrows, c and d). Scale bars represent 10 μm. (e, f)
Quantiﬁcation using the ImageJ software showing percent of cells with pseudopods was signiﬁcantly increased following treatment with
either siRNA2 or 3 (e, blue and red bars) as was the length of pseudopods per cell (f, blue and red bars). In (e), ∗ denotes signiﬁcant
diﬀerence between scrambled siRNA negative control (orange bar) and siRNA(2) (blue bar), p = 0 002; # denotes signiﬁcant diﬀerence
between scrambled siRNA negative control (orange bar) and siRNA(3) (red bar), p = 0 009. In (f), ∗ denotes signiﬁcant diﬀerence between
scrambled siRNA negative control (orange bar) and siRNA(2) (blue bar), p = 0 002; # denotes signiﬁcant diﬀerence between scrambled
siRNA negative control (orange bar) and siRNA(3) (red bar), p = 0 009. Data in (e) and (f) are representative of 4 independent
experiments ± S E M

together, these results suggest an activation of microglia by
nApoE41-151 that occurs at least in part by changes in gene
expression of CXorf56 and TNFα.

4. Discussion
A central question in AD is determining how harboring the
APOE4 allele translates molecularly into an increased risk
for dementia. One possibility is the apoE4 protein may lead
to enhanced inﬂammation that has long been documented
in the AD [7, 21–25]. Emerging data suggests that apoE4

may promote pathology associated with AD through a
gene-regulating mechanism. Thus, data from our lab and
others have documented a nuclear localization for apoE4 that
may lead to gene expression changes [15]. Recently, we dem
onstrated nuclear localization of an amino-terminal frag
ment of apoE4 nApoE41-151 within microglia of the human
AD brain and within BV2 microglia cells [8, 15]. BV2 cells
are a well-characterized, extensively employed model system
for microglia. Studies have demonstrated that BV2 cells are a
valid substitute for primary microglia in many experimental
settings, including complex cell-cell interaction studies [26].
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Figure 5: Treatment of BV2 microglial cells with an amino-terminal fragment of apoE4 leads to the downregulation of CXorf56. (a) BV2 cells
were treated for 5 hours with 25 μg/mg nApoE41-151 (blue bar) or with an equivalent concentration of full-length apoE4 (red bar). Following
treatment, RNA was extracted and RT qPCR was performed. Data indicated a signiﬁcant decrease in the expression of the CXorf56
homologue following treatment, p = 0 0002, while full-length apoE4 had no signiﬁcant eﬀect. (b, c) Western blot analysis utilizing an anti
CXorf56 antibody (1 : 500) conﬁrmed the decreased expression of the CXorf56 protein following treatment of BV2 cells for 24 hrs with
25 μg/ml nApoE41-151. Beta-actin was employed as a loading control utilizing an anti-beta-actin antibody (1 : 50K), bottom panel. (c)
Quantitative densitometry analysis of 3 independent experiments showing an overall 74% decrease in the expression of CXorf56 protein
following treatment (∗ denotes p = 5 76 × 10−7 ). Data are representative of 3 independent experiments ± S D (d, e) BV2 cells were left
untreated (d) or treated for 24 hours with nApoE41-151 and stained with the CXorf56 antibody. Following treatment, there was a decrease
in the staining intensity as well as a morphological shift to bipolar, extended pseudopods (arrowheads, e).

For example, this study showed that in response to LPS, 90%
of genes induced by the BV2 cells were also induced by pri
mary microglia. In the current study, employing BV2
microglia cells as a model system, we tested the hypothesis
that the link between harboring the APOE4 allele and inﬂam
mation in AD may be activation of microglia by altering the
expression of speciﬁc proinﬂammatory genes.
In the present study, we identiﬁed a novel protein,
CXorf56, as a potential link between apoE4 and microglia
activation. Very little is known about the CXorf56 gene or
the protein other than it has been recently linked to an
inherited form of intellectual disability [16]. Our results
demonstrate that the CXorf56 protein resides speciﬁcally
within the ER of BV2 microglia and in liver microsomes.
In addition, knockdown of CXorf56 expression led to a dis
tinct morphological shift of BV2 microglia cells to an acti
vated phenotype. Our data suggest that CXorf56 is required
to maintain microglia cells in a round, compact morphology
with little ramiﬁcation. How downregulation of the CXorf56
protein leads to a morphological shift is not known, but it
may occur through the ER stress pathway. Thus, several

studies have linked CNS inﬂammation mediated in part by
the activation of microglia through the ER stress pathway
[27–30]. The ER stress response constitutes a cellular pro
cess that is stimulated by a variety of conditions that disturb
the normal folding of proteins in the ER. Eukaryotic cells
have developed an adaptive mechanism referred to as the
unfolded protein response (UPR), which is aimed at clearing
unfolded proteins and restoring ER homeostasis [31]. It may
be that the function of CXorf56 is somehow delegated to
maintaining the functioning of UPR, although future studies
will be needed to assess this hypothesis.
A key outcome of the present study was identifying a
novel pathway by which an amino-terminal fragment of
apoE4 (nApoE41-151) may lead to microglia activation.
Although it is well established that harboring the APOE4
allele enhances dementia risk, the molecular mechanisms
underlying this risk has not been well established. Recent
studies from our lab have supported a novel pathway for
nApoE41-151 whereby localization within the nucleus may
lead to gene expression changes [8, 15]. In the present
study, we now demonstrate that nApoE41-151 leads to the
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binding of the fragment to DNA. The last lane was performed similarly except that the nApoE41-151 fragment was preincubated ﬁrst with
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downregulation of the murine CXorf56 homologue mRNA
and protein resulting in a morphological shift that mir
rored the downregulation of CXorf56 by siRNA constructs.
Additionally, we show that treatment of BV2 microglia cells
with nApoE51-151 led to a 24.5-fold increase in mRNA TNFα
expression, a potent proinﬂammatory cytokine. A corre
sponding 68-fold increase of the secreted TNFα protein was
detected in the media following ELISA analysis. We also
observed a parallel 59-fold increase in the secretion of the
IL-1beta cytokine. Finally, we demonstrate a speciﬁc interac
tion of the nApoE41-151 fragment with the mouse TNFα pro
moter region. In contrast, no speciﬁc interaction of fulllength apoE4 with this promoter region was observed. In
pathological conditions, microglia produce large amounts
of TNFα that serves as an important component of neuroin
ﬂammatory response that is associated with several neuro
logical disorders including AD [32–34]. In addition, the
secretion of TNFα and IL-1beta serves as a classic signature
for microglia activation as has been observed in AD [35]. It
is noteworthy that in our studies we treated cells with a
concentration of 25 μg/ml of nApoE41-151. In the previous
study, the levels of apoE4 in the cerebral spinal ﬂuid (CSF)
were measured as being approximately 3-5 μg/ml [20]. Also,
we observed inconsistent eﬀects of 10 μg/ml nApoE41-151 on
the downregulation of the CXorf56 protein, and overall, this
concentration of nApoE41-151 had no statistical eﬀect on the
downregulation of the CXorf56 protein. Although the con
centration of nApoE41-151 used was within an order of mag
nitude, future studies should examine whether lower
concentrations of the nApoE41-151 fragment lead to signiﬁ
cant changes in cytokine levels in order to put our current
ﬁndings in a more physiological context.
We also examined whether downregulation of the
CXorf56 protein led to changes in TNFα levels similar to
what was observed for the nApoE4 fragment. Following
treatment of cells with siRNA to CXorf56, we actually
observed a slight decrease in the TNFα mRNA levels (82%
of control levels). These results suggest that the CXorf56
associated changes in morphology are distinct from the
upregulation of TNFα and that these two separate phenom
ena are associated with nApoE41-151 fragment exposure but
are not necessarily directly related.

5. Conclusions
Collectively, these data suggest that apoE4 may promote the
activation of microglia by a gene-regulatory mechanism
involving a newly identiﬁed protein, CXorf56 as well as
TNFα. These results suggest a novel role for apoE4 and pro
vide a possible link to the inheritance of this allele to inﬂam
mation associated with AD. Future studies should be directed
towards replicating these ﬁndings in primary microglia cul
tures or in induced pluripotent stem cells.
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included within the article.
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Supplementary Materials
Fig. S1: confocal labeling of two diﬀerent markers in BV2
microglial cells. The green image in (A) is showing the use
of the cytochrome C antibody, the red label is showing the
use of the CXorf56 antibody (B), and (C) is showing the over
lap image. Fig. S2: representative Western blot analysis using
the CXorf56 antibody in increasing amounts of liver micro
somes. The data show the presence of a single 34 kDA band
corresponding to the molecular weight of native CXorf56.
Fig. S3: quantitative analysis of BV2 microglia toxicity by
measuring the release of LDH in the media. The data show
untreated, control cells (blue bar) and the following treat
ment with the apoE4 1-151 amino-terminal fragment
(orange bar). There was no signiﬁcant diﬀerence in cytotox
icity following treatment. (Supplementary Materials)

References
[1] Alzheimer's Association, “2018 Alzheimer’s disease facts and
ﬁgures,” Alzheimer's & Dementia, vol. 14, no. 3, pp. 367–429,
2018.
[2] P. L. McGeer, S. Itagaki, H. Tago, and E. G. McGeer, “Reactive
microglia in patients with senile dementia of the Alzheimer
type are positive for the histocompatibility glycoprotein
HLA-DR,” Neuroscience Letters, vol. 79, no. 1-2, pp. 195–
200, 1987.
[3] P. L. McGeer, S. Itagaki, B. E. Boyes, and E. G. McGeer, “Reac
tive microglia are positive for HLA-DR in the substantia nigra
of Parkinson’s and Alzheimer’s disease brains,” Neurology,
vol. 38, no. 8, pp. 1285–1291, 1988.

12
[4] M. Zhu, X. Wang, L. Sun, M. Schultzberg, and E. Hjorth, “Can
inﬂammation be resolved in Alzheimer’s disease?,” Therapeu
tic Advances in Neurological Disorders, vol. 11, 2018.
[5] L. J. van Eldik, M. C. Carrillo, P. E. Cole et al., “The roles of
inﬂammation and immune mechanisms in Alzheimer’s dis
ease,” Alzheimer's & Dementia: Translational Research & Clin
ical Interventions, vol. 2, no. 2, pp. 99–109, 2016.
[6] M. Eisenstein, “Genetics: ﬁnding risk factors,” Nature, vol. 475,
no. 7355, pp. S20–S22, 2011.
[7] Y. Shi, K. Yamada, S. A. Liddelow et al., “ApoE4 markedly
exacerbates tau-mediated neurodegeneration in a mouse
model of tauopathy,” Nature, vol. 549, no. 7673, pp. 523–
527, 2017.
[8] J. E. Love, R. J. Day, J. W. Gause et al., “Nuclear uptake of an
amino-terminal fragment of apolipoprotein E4 promotes cell
death and localizes within microglia of the Alzheimer’s disease
brain,” International Journal of Physiology, Pathophysiology
and Pharmacology, vol. 9, no. 2, pp. 40–57, 2017.
[9] J. H. Lee, E. H. Kam, S. Y. Kim et al., “Erythropoietin attenu
ates postoperative cognitive dysfunction by shifting macro
phage activation toward the M2 phenotype,” Frontiers in
Pharmacology, vol. 8, p. 839, 2017.
[10] T. T. Rohn, L. W. Catlin, K. G. Coonse, and J. W. Habig, “Iden
tiﬁcation of an amino-terminal fragment of apolipoprotein E4
that localizes to neuroﬁbrillary tangles of the Alzheimer’s dis
ease brain,” Brain Research, vol. 1475, pp. 106–115, 2012.
[11] E. Meijering, M. Jacob, J. C. F. Sarria, P. Steiner, H. Hirling,
and M. Unser, “Design and validation of a tool for neurite trac
ing and analysis in ﬂuorescence microscopy images,” Cytome
try, vol. 58A, no. 2, pp. 167–176, 2004.
[12] P. Vallotton, R. Lagerstrom, C. Sun et al., “Automated analysis
of neurite branching in cultured cortical neurons using HCAVision,” Cytometry, vol. 71A, no. 10, pp. 889–895, 2007.
[13] P. T. Xu, D. Schmechel, T. Rothrock-Christian et al.,
“Human apolipoprotein E2, E3, and E4 isoform-speciﬁc
transgenic mice: human-like pattern of glial and neuronal
immunoreactivity in central nervous system not observed
in wild-type mice,” Neurobiology of Disease, vol. 3, no. 3,
pp. 229–245, 1996.
[14] J. K. Boyles, R. E. Pitas, E. Wilson, R. W. Mahley, and J. M.
Taylor, “Apolipoprotein E associated with astrocytic glia of
the central nervous system and with nonmyelinating glia of
the peripheral nervous system,” The Journal of Clinical Investi
gation, vol. 76, no. 4, pp. 1501–1513, 1985.
[15] T. T. Rohn and Z. D. Moore, “Nuclear localization of apo
lipoprotein E4: a new trick for an old protein,” Interna
tional Journal of Neurology and Neurotherapy, vol. 4, no. 2,
2017.
[16] A. Verkerk, S. Zeidler, G. Breedveld et al., “CXorf56, a den
dritic neuronal protein, identiﬁed as a new candidate gene
for X-linked intellectual disability,” European Journal of
Human Genetics, vol. 26, no. 4, pp. 552–560, 2018.
[17] H. Kettenmann, U. K. Hanisch, M. Noda, and A. Verkhratsky,
“Physiology of microglia,” Physiological Reviews, vol. 91, no. 2,
pp. 461–553, 2011.
[18] S. J. Pelletier, M. Lagace, I. St-Amour et al., “The morphologi
cal and molecular changes of brain cells exposed to direct cur
rent electric ﬁeld stimulation,” The International Journal of
Neuropsychopharmacology, vol. 18, no. 5, 2015.
[19] D. Cizkova, S. Devaux, F. le Marrec-Croq et al., “Modulation
properties of factors released by bone marrow stromal cells

Oxidative Medicine and Cellular Longevity

[20]

[21]

[22]
[23]

[24]

[25]

[26]

[27]

[28]

[29]

[30]

[31]

[32]

[33]

on activated microglia: an in vitro study,” Scientiﬁc Reports,
vol. 4, no. 1, p. 7514, 2014.
T. Miida, F. Yamazaki, M. Sakurai et al., “The apolipoprotein E
content of HDL in cerebrospinal ﬂuid is higher in children
than in adults,” Clinical Chemistry, vol. 45, no. 8, pp. 1294–
1296, 1999.
M. F. Uchoa, V. A. Moser, and C. J. Pike, “Interactions between
inﬂammation, sex steroids, and Alzheimer’s disease risk fac
tors,” Frontiers in Neuroendocrinology, vol. 43, pp. 60–82,
2016.
R. E. Tanzi, “The genetics of Alzheimer disease,” Cold Spring
Harbor Perspectives in Medicine, vol. 2, no. 10, 2012.
L. Caberlotto, L. Marchetti, M. Lauria, M. Scotti, and S. Parolo,
“Integration of transcriptomic and genomic data suggests can
didate mechanisms for APOE4-mediated pathogenic action in
Alzheimer’s disease,” Scientiﬁc Reports, vol. 6, no. 1, article
32583, 2016.
L. W. Bonham, R. S. Desikan, J. S. Yokoyama, and for the Alz
heimer’s Disease Neuroimaging Initiative, “The relationship
between complement factor C3, APOE ε4, amyloid and tau
in Alzheimer’s disease,” Acta Neuropathologica Communica
tions, vol. 4, no. 1, p. 65, 2016.
F. M. Marottoli, Y. Katsumata, K. P. Koster, R. Thomas, D. W.
Fardo, and L. M. Tai, “Peripheral inﬂammation, apolipopro
tein E4, and amyloid-β interact to induce cognitive and cere
brovascular dysfunction,” ASN Neuro, vol. 9, no. 4, 2017.
A. Henn, S. Lund, M. Hedtjärn, A. Schrattenholz, P. Pörzgen,
and M. Leist, “The suitability of BV2 cells as alternative model
system for primary microglia cultures or for animal experi
ments examining brain inﬂammation,” ALTEX, vol. 26,
no. 2, pp. 83–94, 2009.
Y. Ha, H. Liu, Z. Xu et al., “Endoplasmic reticulum stressregulated CXCR3 pathway mediates inﬂammation and neuro
nal injury in acute glaucoma,” Cell Death & Disease, vol. 6,
no. 10, article e1900, 2015.
S. Vodret, G. Bortolussi, J. Jašprová, L. Vitek, and A. F. Muro,
“Inﬂammatory signature of cerebellar neurodegeneration dur
ing neonatal hyperbilirubinemia in Ugt1 -/- mouse model,”
Journal of Neuroinﬂammation, vol. 14, no. 1, p. 64, 2017.
B. Chantong, D. V. Kratschmar, A. Lister, and A. Odermatt,
“Inhibition of metabotropic glutamate receptor 5 induces cel
lular stress through pertussis toxin-sensitive Gi-proteins in
murine BV-2 microglia cells,” Journal of Neuroinﬂammation,
vol. 11, no. 1, p. 190, 2014.
I. Bellezza, S. Grottelli, A. L. Mierla et al., “Neuroinﬂammation
and endoplasmic reticulum stress are coregulated by cyclo(
His-Pro) to prevent LPS neurotoxicity,” The International
Journal of Biochemistry & Cell Biology, vol. 51, pp. 159–169,
2014.
R. Sano and J. C. Reed, “ER stress-induced cell death mecha
nisms,” Biochimica et Biophysica Acta (BBA) - Molecular Cell
Research, vol. 1833, no. 12, pp. 3460–3470, 2013.
S. L. Montgomery and W. J. Bowers, “Tumor necrosis
factor-alpha and the roles it plays in homeostatic and degener
ative processes within the central nervous system,” Journal
of Neuroimmune Pharmacology, vol. 7, no. 1, pp. 42–59,
2012.
M. K. McCoy and M. G. Tansey, “TNF signaling inhibition in
the CNS: implications for normal brain function and neurode
generative disease,” Journal of Neuroinﬂammation, vol. 5,
no. 1, p. 45, 2008.

Oxidative Medicine and Cellular Longevity
[34] K. A. Frankola, N. H. Greig, W. Luo, and D. Tweedie, “Target
ing TNF-alpha to elucidate and ameliorate neuroinﬂammation
in neurodegenerative diseases,” CNS & Neurological Disorders
Drug Targets, vol. 10, no. 3, pp. 391–403, 2011.
[35] D. W. Dickson, S. C. Lee, L. A. Mattiace, S. H. C. Yen, and
C. Brosnan, “Microglia and cytokines in neurological disease,
with special reference to AIDS and Alzheimer’s disease,” Glia,
vol. 7, no. 1, pp. 75–83, 1993.

13

